跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2008-001241-26-BG
EUCTR2008-001241-26-BG进行中（未招募）不适用

A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomitant Methotrexate

Biotest AG0 个研究点目标入组 110 人开始时间: 2008年9月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
Biotest AG
入组人数
110
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Female and male patients with active rheumatoid arthritis.
  • •2. ACR criteria for diagnosis of RA, functional class II-III.
  • •3. Active RA as defined by:
  • •= 6 swollen joints on 66 joint count.
  • •= 6 tender joints on 68 joint count.
  • •= 2 of the following: Erythrocyte Sedimentation Rate (ESR) = 28 mm/h, morning stiffness = 45 min., C-reactive Protein (CRP) = 20 mg/L.
  • •4. Age limitations of = 18 years and = 75 years.
  • •5. Body mass index (BMI) between 18 and 30 kg/m2 inclusive, with a body weight between 50 - 110 kg.
  • •6. At least one traditional DMARD inadequate response despite = 3 months of treatment.
  • •7. Concurrent RA medications with stable doses of oral MTX for = 6 months before enrollment (15 to 20 mg per week or as low as 10 mg per week for patients unable to tolerate higher doses). Dose of MTX must be kept constant during study duration (treatment period and follow-up period).
  • •8. Concomitant medication with oral corticosteroids is allowed if stable dose of max. 10 mg (equivalent to prednisone) per day for = 4 weeks prior to Screening.
  • •9. Concomitant medication with NSAIDs is allowed if stable dose for = 4 weeks prior to Screening.
  • •10. No acute or relevant abnormalities in ECG.
  • •11. Laboratory results:
  • •Hemoglobin: = 8.5 g/Dl.
  • •Hematocrit: > 30%.
  • •White Blood Cells (WBC): = 3.5 x 109 cells/L.
  • •CD4 count: > 0.4 x 109 cells/L.
  • •Neutrophils: = 1.5 x 109 cells/L.
  • •Platelets: = 150 x 109 cells/L.
  • •Serum transaminases (ALAT, ASAT): = 3 times the upper limit of normal.
  • •Bilirubin: < 3 mg/Dl.
  • •Alkaline phosphatase: = 2 times the upper limit of normal.
  • •Urea nitrogen: < 1.5 times the upper limit of normal.
  • •12. B-cell count: = 75% of the lower limit of normal.
  • •13. Signed and dated written informed consent.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1. Pre- and concomitant treatment with DMARDs other than Methotrexate, biological product(s), and intraarticular, intramuscular, or intravenous corticosteroids during the last 4 weeks prior to study inclusion and during the entire study.
  • •2. Previous therapy with CD4 mab (note, that a patient who took participation in Step 1 should not be enrolled in Step 2, since this patient has already been treated with BT971).
  • •3. Therapy with Adalimumab or Infliximab in the last 8 weeks and therapy with Etanercept in the last 4 weeks prior to study inclusion and during the entire study.
  • •4. Therapy with Rituximab in the last 6 months prior to study inclusion and during the entire study.
  • •5. Known therapy with Abatacept.
  • •6. Kidney insufficiency as defined by creatinine clearance: < 60 ml/min (Cockcroft Gault equation).
  • •7. History of severe allergic or anaphylactic reaction to proteins of human origin (e.g., vaccination reaction).
  • •8. Known malignancy or history of malignancy within the previous 5 years with no evidence of recurrence.
  • •9. History of clinically significant major disease, i.e., severe heart/lung disease NYHA = 3 (New York Heart Association: class III: patients with marked limitation of activity; comfortable only at rest), autoimmune disease.
  • •10. Serious local (e.g., abscess) or systematic infection (e.g., pneumonia, septicaemia) within previous 3 months.
  • •11. Vaccinated with live, live attenuated, and/or killed vaccines in the previous 3 months prior to the first administration of the study drug.
  • •12. Positive diagnosis for acute or chronic infections (i.e., HBV, HCV, HIV).
  • •13. History of positive diagnosis for active tuberculosis.
  • •14. History of or recurrent acute inflammatory joint disease other than RA.
  • •15. Known immune deficiency.
  • •16. History of lymphoproliferative disease, including lymphoma and lymphadenopathy.
  • •17. History of clinically significant drug or alcohol abuse.
  • •18. The patient, planned to be enrolled is an employee of any involved study investigator or any involved institution including the study sponsor.
  • •19. Joint surgery within 2 months prior to Screening.
  • •20. Pregnant or nursing women, or woman of childbearing potential who are not using an effective contraceptive method during the study and at least four months after the last administration of study drug (e.g., oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, female sterilization, or condoms). Male patients should also maintain reliable contraceptive methods during the entire study participation and at least four months after the last study drug administration.
  • •21. Participation in another clinical trial within 90 days before entering the study or during the study.
  • •22. Inability or lacking motivation to participate in the study.

研究者

发起方
Biotest AG

相似试验

进行中（未招募）
不适用
A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomitant Methotrexate - n.a.Active rheumatoid arthritis, functional class II-IIIMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2008-001241-26-HUBiotest AG110
进行中（未招募）
1 期
Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU).Chronic venous ulcers (CVU)MedDRA version: 21.1Level: LLTClassification code 10066677Term: Chronic leg ulcerSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2020-004960-24-DERHEACELL GmbH & Co. KG200
进行中（未招募）
1 期
Effect of intranasal oxytocin on sosial cogitive tasks in autism spectrum disorderAutism spectrum disorder
EUCTR2014-005452-26-NOOptiNose AS18
招募中
1 期
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
CTIS2023-505316-37-00Recordati AG72
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled, dose finding study of R126638 given as a single or repeat dose in oral solution vs placebo in the treatment of pityriasis versicolor. - Dose finding study of R126638 in pityriasis versicolor
EUCTR2005-004852-11-SEBarrier Therapeutics Inc.144